Results 221 to 230 of about 4,685 (255)
Some of the next articles are maybe not open access.
Remimazolam in neuroanesthesia
Current Opinion in AnaesthesiologyPurpose of review Remimazolam is a novel ultrashort-acting benzodiazepine that has recently gained attention for its potential benefits in neuroanesthesia. This review aims to critically assess the latest evidence regarding its hemodynamic properties, neurophysiological monitoring compatibility, and recovery profile while ...
Abramovich, Igor +2 more
openaire +2 more sources
Drugs, 2020
Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation.
openaire +2 more sources
Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation.
openaire +2 more sources
The Metabolism of the New Benzodiazepine Remimazolam
Current Drug MetabolismBackground:: Remimazolam (RMZ) is a novel ultrashort-acting benzodiazepine used for sedation by intravenous administration. The pharmacophore of RMZ includes a carboxyl ester group sensitive to esterase- mediated hydrolysis, which is the primary path of metabolic elimination.
Wolfgang Schmalix +3 more
openaire +2 more sources
Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children
British Journal of Anaesthesia, 2023J Schüttler +2 more
exaly
Sedation outcomes for remimazolam, a new benzodiazepine
Journal of Oral Science, 2021Yoshiyuki Oi
exaly